Proshares UltraPro NASDAQ Biotechnology
UBIO
UBIO was delisted on the 27th of March, 2020.
9 hedge funds and large institutions have $4.17M invested in Proshares UltraPro NASDAQ Biotechnology in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.
233% more capital invested
Capital invested by funds: $1.25M → $4.17M (+$2.92M)
50% more funds holding
Funds holding: 6 → 9 (+3)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$1.68M |
| 2 |
VF
Virtu Financial
New York
|
+$396K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$291K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$269K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$63.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Cutler Group
San Francisco,
California
|
-$9.35K |
| 2 |
Morgan Stanley
New York
|
-$31 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $1.78M | +$1.68M | +53,809 | New |
|
|
VF
2
Virtu Financial
New York
| $1.18M | +$396K | +12,703 | +56% |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $790K | +$291K | +9,331 | +65% |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $286K | +$269K | +8,641 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $68K | +$63.7K | +2,045 | New |
|
|
6
Morgan Stanley
New York
| $30K | -$31 | -1 | -0.1% |
|
|
LTFS
7
Ladenburg Thalmann Financial Services
Miami,
Florida
| $23K | – | – | – |
|
|
AIM
8
Anchor Investment Management
Columbia,
South Carolina
| $9.12K | – | – | – |
|
|
CG
9
Cutler Group
San Francisco,
California
| $3K | -$9.35K | -300 | -75% |
|
UBIO Hedge Fund Activity: Q2 2018 in Review
9 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Proshares UltraPro NASDAQ Biotechnology (UBIO) for Q2 2018, worth a combined $4.17M — up 233% from $1.25M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new UBIO positions and 0 closed out — a net gain of 3 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $1.68M. The largest seller was Cutler Group, cutting an estimated $9.35K.
- 9 institutional investors held Proshares UltraPro NASDAQ Biotechnology (UBIO) as of Q2 2018, up from 6 in Q1 2018.
- Funds reported $4.17M of Proshares UltraPro NASDAQ Biotechnology stock for Q2 2018, up 233% quarter-over-quarter.
- 3 funds opened new Proshares UltraPro NASDAQ Biotechnology positions in Q2 2018 and 0 closed out, a net change of +3 holders.
- The largest Proshares UltraPro NASDAQ Biotechnology buyer in Q2 2018 was Jane Street, an estimated $1.68M added.
- The largest Proshares UltraPro NASDAQ Biotechnology seller in Q2 2018 was Cutler Group, an estimated $9.35K sold.
Based on aggregated 13F filings for Q2 2018.